NICE technology appraisal TA1026 recommends tirzepatide for managing overweight and obesity. NHS England's interim commissioning guidance decides who actually gets it through the NHS. The two documents do not say the same thing, and the difference between a clinical recommendation and funded access is the story.
This is a regulatory explainer for UK readers. It is a reference piece, not clinical guidance, and it does not address personal use of any medicine.
TA1026: the appraisal
NICE technology appraisal TA1026, Tirzepatide for managing overweight and obesity, recommends tirzepatide as an option for managing overweight and obesity, alongside a reduced-calorie diet and increased physical activity, within specialist weight-management services. The underlying clinical recommendation is for adults with a BMI of at least 35 (32.5 with adjustment for ethnicity) and at least one weight-related comorbidity.
The appraisal committee recorded high parameter uncertainty and high decision risk given the potential size of the eligible population. It referenced an acceptable cost-effectiveness threshold of £20,000 per QALY gained, consistent with the earlier semaglutide appraisal.
The funding variation and the commissioning gap
Alongside TA1026, NICE issued a funding variation for tirzepatide, and NHS England published interim commissioning guidance to implement both across the first three years of delivery in England. The guidance, last reviewed in April 2026, sets out eligible patient cohorts, a prioritisation strategy, and phased implementation across specialist weight-management services and primary care settings.
The practical consequence is that NICE's underlying clinical recommendation is broader than current NHS primary-care access. Access is staged by cohort, and being eligible under TA1026 does not by itself mean eligibility for NHS primary-care prescribing. NICE has separately published local-formulary information and prescribing checklists covering initial assessment, counselling and follow-up.
The April 2026 GP contract change
From 1 April 2026, tirzepatide prescribing sits within the 2026/27 GP contract as a Quality and Outcomes Framework (QOF) indicator, OB005, which supports consideration of weight-management pharmacotherapies in line with the NICE obesity guideline NG246 and TA1026. It is an optional indicator: GP practices may choose whether to take part. One consequence is that two practices serving similar populations may differ in whether they prescribe tirzepatide for weight management at all. Related indicators OB004 and OB005 align with the NICE quality standard QS121 on overweight, obesity and central adiposity.
Type 2 diabetes: the February 2026 NG28 update
NICE's type 2 diabetes guideline, NG28, was updated in February 2026. At that date, its class-level recommendations for GLP-1 receptor agonists covered liraglutide, dulaglutide and semaglutide, with subcutaneous semaglutide restricted to doses up to 1 mg once weekly. Tirzepatide, a dual GIP and GLP-1 receptor agonist, is addressed separately: NICE's technology appraisal recommends it as an alternative to GLP-1 receptor agonists for adults whose type 2 diabetes is insufficiently controlled on triple therapy with metformin and two other oral antidiabetic medicines, among other criteria. The February 2026 update also created a cardiovascular-independent prescribing stream for people with established atherosclerotic cardiovascular disease. NICE has separately been evaluating semaglutide for preventing major cardiovascular events in a defined population.
What this means for readers of this library
Tirzepatide (Mounjaro) is a prescription-only medicine in the UK, supplied on prescription and subject to MHRA oversight. It is not a research compound, and the compound profile in this library describes the published trial record, not personal use. GLP-1 and dual GIP/GLP-1 medicines carry UK safety warnings, including strengthened warnings on acute pancreatitis issued in January 2026, and suspected side effects are reported to the MHRA through the Yellow Card scheme. Supply outside the licensed route, including grey-market vials sold as research material, is a separate and unregulated market covered elsewhere in this library.
Evidence and access are not the same thing
The TA1026 position illustrates a distinction that matters across this library: a positive technology appraisal establishes clinical and cost effectiveness for a defined population, not universal access. Commissioning guidance and contract incentives decide what reaches patients in practice. For a medicine as widely discussed as tirzepatide, the commissioning layer is where the UK access story is actually written.
This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.